Smidt Heart Institute, Cedars-Sinai

A patient’s life can change for the betterin a heartbeat. Even heart failure patients who

AN N UAL R E P O RT 2019

... can change the trajectory of cardiac care. have currently limited treatment options and a poor prognosis can gainnew hope from the workconductedat the Smidt Heart Institute. Through advances in areas such as minimallyinvasive procedures andcell therapy, weare forginga new trajectory in cardiac care thatpromises to have a global impact on heart health. Our researchers share a determination to help everyone who struggles with heart disease—including populationsthat have too long been neglected. This reports highlights some of our most recent accomplishments. With our hearts and minds focused on new approaches

HEARTS AND MINDS day, we challenge the status quo in cardiac care with confidence that the next big discovery is AT THE just around the corner.

LEADING EDGE... to healing, we operateat the leading edge. Each

SMIDT HEART INSTITUTE

9 1 0 2 T R O P E R L AU N N A

STRAEH SDNIM DNA EHT TA G N I DA EL ...EGDE ETUTITSNI TRAEH TDIMS

... can change the trajectory of cardiac care.

A patient’s life can change for the better in a heartbeat. Even heart failure patients who have currently limited treatment options and a poor prognosis can gain new hope from the work conducted at the Smidt Heart Institute. Through advances in areas such as minimally invasive procedures and cell therapy, we are forging a new trajectory in cardiac care that promises to have a global impact on heart health. Our researchers share a determination to help everyone who struggles with heart disease— including populations that have too long been neglected. This report highlights some of our most recent accomplishments. With our hearts and minds focused on new approaches to healing, we operate at the leading edge. Each day, we challenge the status quo in cardiac care with confidence that the next big discovery is just around the corner.

1

SMIDT HEART INSTITUTE 2019 ANNUAL REPORT

Dear Colleague,

What an incredible year this has been for the heart programs at Cedars-Sinai.

• Thanks to a generous philanthropic gift from Eric and Susan Smidt, we are now the Smidt Heart Institute.

• The Smidt Heart Institute was recognized by U.S. News & World Report as one of the nation’s top three programs for cardiology and heart surgery.

• We perform more heart transplants than any other center, including 111 in FY18.

Our outcomes continue to surpass benchmarks.

• Our structural heart disease program targets all major heart valves with innovative interventions. New percutaneous approaches to closing a patent ductus streamline the care of newborns, while transcatheter valve replacements give new life to elderly patients too frail for conventional surgery.

• We identified a new biomarker for heart failure with preserved ejection fraction (HFpEF), one of the leading enigmas in modern cardiac medicine.

Meanwhile, our investigators have elucidated the mechanisms of sudden death in a preclinical model of HFpEF, which may help in understanding why this disease is so resistant to conventional therapies.

• The Barbershop Study, conceived and executed here, validated a new paradigm for treating neglected populations at high risk for hypertension: Take testing and treatment to the patient, and they will respond.

• The Barbra Streisand Women’s Heart Center continues to challenge our preconceptions regarding heart disease: It affects women at high rates and with different presentations than in men.

The enclosed 2019 Annual Report tells the whole story. As always, we welcome your comments and questions. We would be particularly pleased to help you with any challenging patients you may wish to refer to us. Do not hesitate to contact me at heartinstitute@cshs.org or visit our website at cedars-sinai.org/heart.

Sincerely, Eduardo Marbán, MD, PhD Mark Siegel Family Foundation Distinguished Professor and Director, Smidt Heart Institute Cedars-Sinai Medical Center

2

6 8 10 13 HEALING THE IMPOSSIBLY INJURED HEART

THE BEAUTY OF MINIMALISM IN CARDIAC CARE

GIVING NEGLECTED POPULATIONS A VOICE

METRICS

3

SMIDT HEART INSTITUTE 2019 ANNUAL REPORT

6 8 01 31 FO Y TUA EB EHT N I M S IL A M I N I M ERAC CAIDRAC

E HT G N IL A E H YLBISSOPMI TR A E H D E R U J N I

DETCELGEN GNIVIG SNOITA LUPOP ECIOV A

S C I RT E M

4

EHT FO YTUAEB M S IL A M I N I M CAIDRAC NI ERAC

F O RE B M U N L A N O I T N E VR E T N I D N A YG OL O I D R A C YG OL O I SY HP ORT CELE SE R U DE C ORP 8 10 2 N I D E M R OF R E P

5

SMIDT HEART INSTITUTE 2019 ANNUAL REPORT

HEALING THE IMPOSSIBLY INJURED HEART

NUMBER OF HEART TRANSPLANTS PERFORMED IN FY18, MORE THAN ANY OTHER HOSPITAL IN THE NATION, WITH BETTER-THAN-EXPECTED OUTCOMES

6

The future is no distant horizon to our

• We have a number of clinical

forward-thinking scientists. It is here

trials underway that use cells as

and now, in discoveries that enable us to

with advanced cardiovascular

heal the impossibly injured heart. Our investigators are pioneers in developing the power of cells and exosomes to reverse heart attack damage. We are also making progress fighting diseases such as Duchenne muscular dystrophy with novel cell approaches developed

therapeutic agents in patients disease who do not respond to conventional therapy.

• Our researchers are examining which biomarkers can best provide information about how a patient responds when treated either with conventional or experimental therapies.

• More than 1,000 patients have undergone transplants

here at the Smidt Heart Institute, which

at Cedars-Sinai since the

appear to improve both heart and

established in 1988.

skeletal muscle function for patients

Heart Transplant Program was

• From 2010 through 2014, our

with this devastating degenerative

comprehensive approach to

disorder. Even for the highest-risk

patients living more than a year

patients with advanced heart disease, we offer hope: Cedars-Sinai performs more heart transplants than any other medical facility in the nation, with better-than-expected outcomes. Using novel antirejection technologies, we routinely transplant organs into patients who would be rejected as candidates at most other centers. Our advanced heart disease program also offers the most state-of-the-art options available in cardiac support devices, both durable and temporary. All this innovation adds up to something of immeasurable value to critically ill patients: the gift of time.

7

SMIDT HEART INSTITUTE 2019 ANNUAL REPORT

care led to 91 percent of our after their heart transplant. This surpassed the projected survival rate determined by the United Network for Organ Sharing.

• We’re developing more effective immunosuppression drug regimens with fewer side effects to fight organ rejection.

THE BEAUTY OF MINIMALISM IN CARDIAC CARE

TRANSCATHETER AORTIC VALVE REPLACEMENT

MITRACLIP

TRANSCATHETER PULMONARY VALVE REPLACEMENT

TRANSCATHETER MITRAL VALVE REPLACEMENT

INTRACORONARY STEM CELL INJECTION

NUMBER OF CUTTING-EDGE PROCEDURES PERFORMED IN FY18

PERCUTANEOUS LEFT VENTRICULAR ASSIST DEVICES

PERCUTANEOUS CLOSURE OF LEFT ATRIAL APPENDAGE OCCLUSION

EXTRACORPOREAL MEMBRANE OXYGENATION

8

597 221 17 28 14

56 116 60

Minimalists rocked the art world

• Our team has performed more

with their reductive vision. We’re

percutaneous mitral and aortic

doing the same in the medical world

U.S. medical center.

with our less-is-more approach to

valve procedures than any other

• Today, we can offer new hope

heart procedures. Our strides as a

to patients with the poorest

leader in performing percutaneous

demonstration that catheter-

mitral valve repairs and aortic valve

prognoses, thanks to the based repair of regurgitant mitral valves can improve

replacements make recovery so

survival and enhance quality

much faster, and outcomes so much

heart failure.

better, that traditional surgery is no longer required in many cases. We’re at the forefront of the next wave of clinical studies that may lead to less invasive, more effective techniques becoming part of routine clinical practice. The beauty of minimalism in modern heart medicine is that we can now offer new treatment

of life in patients with severe › We recruited more patients than any other institution to the mitral valve-repair study, conducted at 78 sites in the U.S. and Canada. › The remarkable results, reported recently in the New England Journal of Medicine, included significant reductions in death rates and hospitalizations as well as improved quality of life.

• We bring the benefits of the most advanced minimally

options for people too elderly or frail

invasive techniques to patients

to endure open-heart surgery. We

training practitioners around the

are rewriting textbook medicine with a revolution in cardiac care that maximizes patients’ potential to heal and regain active lives.

9

SMIDT HEART INSTITUTE 2019 ANNUAL REPORT

far beyond Cedars-Sinai by world to perform these highly specialized procedures.

GIVING NEGLECTED POPULATIONS A VOICE

NUMBER OF WOMEN ENROLLED IN CEDARSSINAI’S WARRIOR PROJECT, THE LARGEST CLINICAL TRIAL EVER TO STUDY WOMEN WITH SIGNS AND SYMPTOMS OF ISCHEMIA, BUT NO OBSTRUCTIVE CORONARY DISEASE

10

Deep expertise across all specialties enables the Smidt Heart Institute to improve prognosis and quality of life for a broad spectrum of patients— including the most underserved populations. Among those at highest risk are African-American men, who are affected more by dangerously high blood pressure than almost any other group in the world. Distrust of doctors tends to be a barrier to treatment, so we designed and executed a clinical trial involving 52 black-owned barbershops across Los Angeles. Barbers were trained to measure blood pressure, and to offer their hypertensive customers on-site management by Cedars-Sinai pharmacists, along with a cut and shave. It worked. We saw major drops in blood pressure and positive changes in health habits. We’re also advancing knowledge of female-pattern heart disease to reverse decades of neglect of women as subjects in mainstream heart research. And we’re creating ingenious techniques to correct congenital heart defects in our tiniest patients—premature babies not much larger than the palm of a hand.

11

SMIDT HEART INSTITUTE 2019 ANNUAL REPORT

• The Los Angeles Barbershop Blood Pressure Study involved 319 black male barbershop patrons with systolic blood pressure of 140 mm Hg or greater. On average, their systolic blood pressure dropped from 153 mm Hg at the start of the study to 126 mm Hg after six months. And more than 63 percent of participants brought their blood pressure below the recommended 130/80.

• The Barbra Streisand Women’s Heart Center’s WARRIOR project is the largest clinical trial ever to study women who have symptoms of ischemic heart disease but whose arteries appear clear on standard tests.

• Our researchers have broadened knowledge of the factors that heighten a woman’s risk, such as adverse pregnancy outcomes, estrogen deficiency and premature menopause.

• We’ve launched a pilot study and research registry of Takotsubo syndrome, or broken-heart syndrome, a largely reversible but potentially life-threatening condition that occurs almost exclusively in women.

• The Smidt Heart Institute’s Guerin Family Congenital Heart Program treats patients from intrauterine life through adolescence—and across adulthood. Our experts have led development of a technique for navigating a tiny device through a catheter into a vessel of a premature baby’s heart to treat a life-threatening congenital heart condition called patent ductus arteriosus. This research could revolutionize cardiac care for preemies.

pohsrebraB selegnA soL ehT • devlovni ydutS erusserP doolB p o h s r e b r a b e l a m k c al b 9 1 3 doolb cilotsys htiw snortap r o g H m m 0 4 1 fo e r u s s e r p rieht ,egareva nO .retaerg deppord erusserp doolb cilotsys fo trats eht ta gH mm 3 51 morf ret fa gH mm 621 ot yduts eht 3 6 naht erom dnA . shtnom xis thguorb stnapicitrap fo tnecrep eht woleb erusserp doolb rieht . 08/031 dednemmocer s’nemoW dnasiertS arbraB ehT • tcejorp ROIRRAW s’retneC traeH reve lairt lacinilc tsegral eht si evah ohw nemow yduts ot traeh cimehcsi fo smotpmys raeppa seiretra esohw tub esaesid .stset dezidradnats no raelc evah srehcraeser ruO • eht fo egdelwonk denedaorb s’namow a nethgieh taht srotcaf ycnangerp esrevda sa hcus ,ksir ycneicfied negortse , semoctuo .esuaponem erutamerp dna dna yduts tolip a dehcnual ev’eW • obustokaT fo yrtsiger hcraeser traeh-nekorb ro ,yhtapoymoidrac elbisrever ylegral a ,emordnys gninetaerht-efil yllaitnetop tub tsomla srucco taht noitidnoc .nemow ni ylevisulcxe nireuG s’etutitsnI traeH tdimS ehT • margorP traeH latinegnoC ylimaF eniretuartni morf stneitap staert dna—ecnecseloda hguorht efil strepxe ruO .doohtluda ssorca a fo tnempoleved del evah ynit a gnitagivan rof euqinhcet otni retehtac a hguorht ecived s’ybab erutamerp a fo lessev a gninetaerht-efil a taert ot traeh dellac noitidnoc traeh latinegnoc sihT .susoiretra sutcud tnetap ezinoitulover dluoc hcraeser .seimeerp rof erac caidrac 12

seitl aiceps ll a ssorca esit rep xe peeD ot etu titsnI t r aeH tdimS eht selbane efil fo y til auq dn a sison gorp evorpmi —stneitap fo mu rtceps daorb a rof dev resrednu tsom eht gnidulcni tseh gih ta esoht gnom A .snoitalupop ohw ,nem n acirem A-n acir f A er a ksir ylsuoregn ad yb erom detceff a er a yn a tsoml a n aht erusserp doolb h gih tsu rtsiD .dlrow eht ni puor g rehto reirr ab a eb ot sdnet srotcod fo dn a den gised ew os ,tnemtaert ot gni vlovni l airt l acinilc a detucexe ssorca spohsrebr ab den wo-kcalb 25 deni art erew srebr aB .selegn A soL ot dn a ,erusserp doolb erusaem ot sremotsuc evisnet rep yh rieht reffo i aniS-sr adeC yb tnemegan am etis-no dn a tuc a hti w gnol a …stsicamr ahp spor d rojam was eW .dekrow tI .evahs segn ahc evitisop dn a erusserp doolb ni gnicn avda osl a er’eW .stibah htl aeh ni t r aeh nret tap-el amef fo egdelwon k tcelgen fo sedaced esrever ot esaesid m aertsni am ni stcejbus sa nemow fo gnitaerc er’ew dn A .hcr aeser t r aeh tcerroc ot seuqin hcet suoinegni tseinit ruo ni stcefed t r aeh l atinegnoc hcum ton seibab eru tamerp—stneitap .dn ah a fo ml ap eht n aht regr al

TOTAL

NONINVASIVE DIAGNOSTICS

167,605 167,019 137,968 137,571

ADVANCED IMAGING

CARDIAC CATHETERIZATIONS

ELECTROPHYSIOLOGY

CARDIOTHORACIC SURGERIES

13

FY17

ALL PROCE DU R E S

FY18

14,532 14,450 11,553 11,146 2,140 2,382

SCIRTEM

1,412 1,470

SMIDT HEART INSTITUTE 2019 ANNUAL REPORT

METRICS

14

167,613 167,019

TOTAL

NONINVASIVE DIAGNOSTICS

137,968 137,571

ADVANCED IMAGING

CARDIAC CATHETERIZATIONS

ELECTROPHYSIOLOGY

CARDIOTHORACIC SURGERIES

15

FY17

14,532 14,450 11,553 11,146 2,140 2,382 1,4201,470

SMIDT HEART INSTITUTE 2019 ANNUAL REPORT

ALL PROCE DU R E S

FY18

CAR DIAC CATH E TE RIZ ATIO NS

FY18

11,553 FY17

11,146 FY16

10,477

PROCEDURE

FY16

FY17

FY18

Angiography

5,896

6,388

6,575

1,637

1,844

2,072

483

579

597

174

199

221

Percutaneous Coronary Intervention Transcatheter Aortic Valve Replacement (TAVR) MitraClip Transcatheter Pulmonary Valve Replacement (TPVR) Transcatheter Mitral Valve Replacement (TMVR)

10

9

17

11

26

28

18

5

3

Valvuloplasty Adult Aortic Valvuloplasty (AVP) Peds AVP

2

2

0

Adult Mitral Valvuloplasty (MVP)

4

3

5

Adult Pulmonary Valvuloplasty (PVP)

1

2

0

Peds PVP

1

3

4

Carotid Angiography/Carotid Stent

42

16

17

1,250

1,136

1,050

13

17

14

613

599

631

Percutaneous Alcohol Septal Ablation for Hypertrophic Cardiomyopathy

20

11

19

Percutaneous Closure of Paravalvular Leak

14

13

14

Adult Atrial Septal Defect (ASD)

17

21

27

Peds ASD

10

11

9

Adult Patent Foramen Ovale (PFO)

Endomyocardial Biopsy Intracoronary Stem Cell Injection/Therapy Intravascular Ultrasound

Percutaneous Closure of Septal Defects

17

24

44

Peds PFO

2

0

3

Adult Ventricular Septal Defect (VSD)

11

6

1

4

2

1

Adult Patent Ductus Arteriosus (PDA) Peds PDA

10

7

13

Percutaneous Left Ventricular Assist Devices

60

57

56

Percutaneous Closure of Left Atrial Appendage Occlusion

141

121

116

16

45

16

10,477

11,146

11,553

Coronary Reactivity Testing TOTAL

16

CUT TING - E DG E PROCE DU R E S

FY18 1,193

FY17 1,132

FY16 1,053

PROCEDURES

FY16

FY17

FY18

483

579

597

174

199

221

10

9

17

TMVR

11

26

28

Intracoronary Stem Cell Injection/Therapy

13

17

14

Adult Atrial Septal Defect (ASD)

17

21

27

Peds ASD

10

11

9

Adult Patent Foramen Ovale (PFO)

TAVR MitraClip TPVR

17

24

44

Peds PFO

2

0

3

Adult Ventricular Septal Defect (VSD)

11

6

1

60

57

56

Percutaneous Left Ventricular Assist Devices Percutaneous Closure of Left Atrial Appendage Occlusion Extracorporeal Membrane Oxygenation (ECMO)

ADVANCE D IMAG ING

TOTAL

516 |||||| |||||| |||||| |||||| ||||||||| |||||||||||||||||||||||||||||||||

|||||| | ||||||| |||||| |||||||||| ||||||| |||||||||||||||||||||||||||||

|||||| |||||| ||||||| ||||||| |||||||||| ||||||||||||||||||||||||||||||

121

116

62

60

1,053

1,132

1,193

MAGNETIC RESONANCE (MRI, MRA, MRV)

4,369 NUCLEAR CARDIOLOGY (SPECT EXAMS AND MRV) 1,660 NUCLEAR CARDIOLOGY PET EXAMS 7,987 CARDIAC CT EXAMS TOTAL 14,532

||||| |||| |||||| |||||| |||||||| |||||||||||||||||||||||||||||||||||||

PROCEDURE Nuclear Cardiology PET Exams Cardiac CT Exams Magnetic Resonance (MRI, MRA, MRV) Nuclear Cardiology (SPECT Exams and MRV) TOTAL

17

141 104

SMIDT HEART INSTITUTE 2019 ANNUAL REPORT

FY16

FY17

FY18

1,725

1,679

1,660

6,495

7,101

7,987

452

555

516

5,072

5,115

4,369

13,744

14,450

14,532

CAR DIOTH O R ACIC SU RG E RIE S

PROCEDURES Coronary Artery Bypass Grafting (CABG) (Isolated) Mitral Valve (MV) Procedures, including CABG* MV Replacement MV Repair Aortic Valve (AV) Procedures, including CABG* AV Replacement AV Repair CABG with Valve Replacement/Repair CABG with Other Non-Valve Procedure

154

146

163

206

188

227

66

61

95

140

127

132

260

243

233

208

203

211

52

40

22

53

71

63

9

8

12

18

14

16

51

93

96

104

62

60

64

32

23

Electrical

205

178

160

Myocardial

33

36

37

Pericardial

11

14

22

23

24

28

Other Noncardiac Thoracic Aortic Surgery

307

239

160

Heart Transplant

128

119

111

Total Artificial Heart

20

3

9

1,646

1,470

1,420

TOTAL

|||||| | ||||||| |||||| |||||| |||||||||| ||||||||||||||||||||||||||||||

||||| ||||| ||||||| ||||||| ||||||||| |||||||||||||||||||||||||||||||||

||||| ||||| |||||| ||||||||| ||||||| ||||||||||||||||||||||||||||||||||

E LEC TRO PHYSIO LOGY

FY18

Ventricular Assist Device

Congenital

CLINICAL TRIALS

FY17

Lung Transplant

ECMO

18

FY16

686

ELECTROPHYSIOLOGY STUDIES

636

BLATION PROCEDURES (SUPRAVENTRICULAR TACHYCARDIA A (SVT)/OTHER SVT/ATRIAL FIBRILLATION/A-FLUTTER)

818

PACEMAKER AND CARDIOVERTER DEFIBRILLATOR IMPLANTATION TOTAL

2,140

||||| ||||| |||||| |||||| |||||||| ||||||||||||||||||||||||||||||||||||

38

SOON TO ENROLL

193

ENROLLING

82

FOLLOW-UP PHASE

TOTAL

313

OUTCO M E S

HEART ATTACK

30-DAY RISK-STANDARDIZED MORTALITY RATE

8.9 %

Cedars-Sinai

13.2 % National

HEART FAILURE

30-DAY RISK-STANDARDIZED MORTALITY RATE

6.4 %

Cedars-Sinai

11.7% National

In data comparing hundreds of major hospitals nationally, Cedars-Sinai has the lowest mortality for myocardial infarction and heart failure.

SOURCE Hospital Compare | All Hospitals | Measure Date Range: July 2014–June 2017

19

SMIDT HEART INSTITUTE 2019 ANNUAL REPORT

S E M OCT U O

KCATTA TRAEH

YAD- 03 DEZIDRADNATS-KSIR ETAR Y TILATROM

%2 . 31 l a n o it a N

% 9. 8

i a ni S -s r a d e C

ERULIAF TRAEH

YAD- 03 DEZIDRADNATS-KSIR ETAR Y TILATROM

%7. 1 1 l a n o it a N

%4. 6

i a ni S -s r a d e C

7102 enuJ - 4102 yluJ :egnaR etaD erusaeM | slatipsoH llA | erapmoC latipsoH ECRUOS

20

3

NOITAN EHT NI

3 4

8 9

9

01

31 51

51

51 61

8102

7102

6102

5102

4102

3102

2102

1102

0102

90 02

8 0 02

traeh dna ygoloidrac rof gniknar lanoitan s’etutitsnI traeH tdimS ehT ”.91–8102 slatipsoH tseB“ s’ tropeR dlroW & sweN . S .U ni 3 .oN ot esor yregrus

21

SMIDT HEART INSTITUTE 2019 ANNUAL REPORT

SGNIK NA R

SA D E K NA R POT EHT FO ENO

RANKINGS

RANKED AS ONE OF THE TOP

3

IN THE NATION

3 4

8 9

9

10

15

15

15

2010

2009

2008

13

2011

2012

2013

2014

2015

2016

2017

2018

16

The Smidt Heart Institute’s national ranking for cardiology and heart surgery rose to No. 3 in U.S. News & World Report’s “Best Hospitals 2018–19.”

22

International Patent Applications

ISSUED

FILED

220 36

|||||| | ||||| ||||||| ||||||| |||||||||| ||||||||||||||||||||||||||||||

||||| |||||| ||||||| ||||||| ||||||||| ||||||||||||||||||||||||||||||||

INTELLECTUAL PROPERTY

FILED

||||| ||||| ||||||| ||||||| ||||||||| |||||||||||||||||||||||||||||||||

R E SE ARCH FU N DING

United States Patent Applications

ISSUED

156 44

12

$15,796,970

FEDERAL AND STATE

$11,659,770

OTHER PEER-REVIEWED

$6,339,648

INDUSTRY TOTAL $ 33,796,388

|||||| | ||||||| ||||| |||||||||| ||||||| ||||||||||||||||||||||||||||||

FY16

FY17

FY18

Federal and State

$10,066,567

$12,907,576

$15,796,970

Other Peer-Reviewed

$13,079,293

$11,641,843

$11,659,770

$6,383,146

$6,535,409

$6,339,648

$29,529,006

$31,084,828

$33,796,388

Industry TOTAL

PEER-REVIEWED ARTICLES

Copyright Registrations

FY16 457

FY17 467

23 SMIDT HEART INSTITUTE 2019 ANNUAL REPORT

FY18 471

NO N INVASIVE DIAG NOSTIC S

ECHO STUDIES 2D Echocardiogram Complete With Doppler With or Without Contrast Rest and Stress Echocardiogram and CV Stress Test and Dobutamine Echocardiography With or Without Contrast Transesophageal Echocardiography With or Without Contrast; May Include 3D Imaging Intima-Media Thickness (IMT) Study TOTAL

Cardiovascular Monitoring Services (Holter Monitor, BPM, Mobile Cardiovascular Telemetry) Tilt Table Cardioversion Pacemaker/Implantable Cardiac Defibrillator (ICD) Device Interrogation and Programming Enhanced External Counterpulsation (EECP) Therapy TOTAL

INPATIENT DISCHARGES

GRAND TOTAL

OUTPATIENT VISITS

FY17

FY18

24,483

27,026

27,226

985

1,126

1,109

3,905

3,750

3,785

36

14

26

29,409

31,916

32,146

89,489

98,423

99,816

3,100

3,850

2,101

55

40

50

396

426

400

2,078

2,360

2,820

766

556

635

95,884

105,655

105,822

125,293

137,571

137,968

OTHER HEART RHYTHM PROCEDURES Electrocardiogram

FY16

6,138

FY17

FY18

6,805

7,215

FY18

34,801 FY17

32,687 FY16

31,907

FOR MORE INFORMATION, PLEASE VISIT CEDARS-SINAI.ORG/HEART 24

FY16

ETUTITSNI TRAEH TDIMS

.dvlB ylreveB 0 078 noilivaP secneicS htlaeH decnavdA 0 063A etiuS 8 4 0 0 9 A C , s e l e g n A s oL 0 033-324- 0 1 3 t raeh/ude.ianis-sradec gro. shsc@ etutitsnit raeh

NO N INVASIVE DIAG NOSTIC S

ECHO STUDIES 2D Echocardiogram Complete With Doppler With or Without Contrast Rest and Stress Echocardiogram and CV Stress Test and Dobutamine Echocardiography With or Without Contrast Transesophageal Echocardiography With or Without Contrast; May Include 3D Imaging Intima-Media Thickness (IMT) Study TOTAL

FY17

FY18

24,483

27,026

27,226

985

1,126

1,109

3,905

3,750

3,785

36

14

26

29,409

31,916

32,146

89,489

98,423

99,816

3,100

3,850

2,101

55

40

50

396

426

400

2,078

2,360

2,820

766

556

635

95,884

105,655

105,822

125,293

137,571

137,968

OTHER HEART RHYTHM PROCEDURES Electrocardiogram Cardiovascular Monitoring Services (Holter Monitor, BPM, Mobile Cardiovascular Telemetry) Tilt Table Cardioversion Pacemaker/Implantable Cardiac Defibrillator (ICD) Device Interrogation and Programming Enhanced External Counterpulsation (EECP) Therapy TOTAL

GRAND TOTAL

FY16

6,138

OUTPATIENT VISITS

INPATIENT DISCHARGES

FY16

FY17

FY18

6,805

7,215

FY18

34,801 FY17

32,687 FY16

31,907

SMIDT HEART INSTITUTE

FOR MORE INFORMATION, PLEASE VISIT CEDARS-SINAI.ORG/HEART

8700 Beverly Blvd., Advanced Health Sciences Pavilion, Suite A3600, Los Angeles, CA 90048 310-423-3300 | cedars-sinai.edu/heart | heartinstitute@cshs.org